Behavioral
Thompson River Pediatrics and Urgent Care, LLC
Thompson River Pediatrics and Urgent Care, LLC was paid $8.00M by Medicaid between Jan 2018 and Dec 2024, across 75 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 27% of everything it billed.
33Billing provider infoTHOMPSON RIVER PEDIATRICS AND URGENT CARE, LLC
JOHNSTOWN, CO 80534
JOHNSTOWN, CO 80534
33aNPI1497155089assigned 09/02/2014
33bProvider typeProfessional Counselor
28Total paid$8.00M
24GClaims154,987
24DCodes billed75
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Professional Counselor providers in Colorado
Rank by total paid#2 of 395
Median peer was paid$51K
This provider vs. median158×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 12,475 | $528K | |
| 2019 | 15,406 | $659K | |
| 2020 | 17,633 | $784K | |
| 2021 | 24,394 | $1.39M | |
| 2022 | 25,390 | $1.70M | |
| 2023 | 28,114 | $1.66M | |
| 2024incomplete | 31,575 | $1.27M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 27% | 24,685 | 20,817 | $2.13M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 18% | 4,161 | 3,483 | $1.43M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 17% | 23,301 | 19,688 | $1.40M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 8.3% | 7,856 | 7,165 | $664K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 7.5% | 16,407 | 15,005 | $599K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 6.0% | 5,843 | 5,310 | $480K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 3.8% | 5,329 | 1,150 | $304K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 3.7% | 3,527 | 3,250 | $296K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 3.1% | 17,225 | 15,446 | $250K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.0% | 3,037 | 2,343 | $81K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,154 | 1,084 | $53K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 551 | 520 | $50K |
63 more codes
| 99174 | <1% | 1,980 | $25K | |
| 90670 | <1% | 2,927 | $25K | |
| 92551 | <1% | 1,421 | $15K | |
| 90461 | <1% | 8,966 | $14K | |
| 96127 | <1% | 1,107 | $14K | |
| 99177 | <1% | 833 | $12K | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 1,059 | $12K |
| 83655 | <1% | 910 | $11K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 67 | $8K |
| 85018 | <1% | 3,699 | $8K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 87 | $7K |
| 90686 | <1% | 2,420 | $7K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 188 | $7K |
| 90698 | <1% | 1,779 | $7K | |
| 0072A | <1% | 112 | $6K | |
| 0071A | <1% | 124 | $6K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 428 | $6K |
| 90677 | <1% | 417 | $6K | |
| 99381 | <1% | 60 | $6K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 391 | $6K |
| 80061 | Lipid panel | <1% | 415 | $5K |
| 36416 | <1% | 4,092 | $4K | |
| 90680 | <1% | 1,344 | $4K | |
| 90651 | <1% | 101 | $4K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 43 | $3K |
| 99173 | <1% | 597 | $3K | |
| H0049 | Alcohol and/or drug screening | <1% | 298 | $3K |
| 99382 | <1% | 32 | $3K | |
| 90633 | <1% | 767 | $3K | |
| 99383 | <1% | 22 | $2K | |
| 90480 | <1% | 43 | $2K | |
| 90697 | <1% | 499 | $2K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,009 | $2K |
| D0145 | Oral evaluation for a patient under three years of age | <1% | 49 | $1K |
| 90619 | <1% | 33 | $1K | |
| 94760 | <1% | 406 | $971.70 | |
| 90710 | <1% | 15 | $942.72 | |
| 90656 | <1% | 438 | $918.05 | |
| 90672 | <1% | 253 | $905.70 | |
| D0190 | <1% | 60 | $858.28 | |
| D1206 | Topical application of fluoride varnish | <1% | 42 | $639.60 |
| 99050 | <1% | 77 | $555.88 | |
| 96380 | <1% | 23 | $460.84 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 37 | $426.32 |
| 90688 | <1% | 942 | $399.11 | |
| 90744 | <1% | 386 | $314.49 | |
| 91321 | <1% | 24 | $273.00 | |
| 90696 | <1% | 15 | $211.98 | |
| 90707 | <1% | 43 | $179.20 | |
| 88720 | <1% | 44 | $172.68 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 14 | $172.37 |
| 90734 | <1% | 13 | $146.62 | |
| 87807 | <1% | 12 | $129.25 | |
| 90660 | <1% | 12 | $115.98 | |
| 90715 | <1% | 41 | $102.20 | |
| 90716 | <1% | 34 | $54.50 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 12 | $30.00 |
| 90685 | <1% | 290 | $22.96 | |
| 90658 | <1% | 26 | $11.50 | |
| 81003 | <1% | 25 | $8.31 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 15 | $3.60 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 37 | $0.73 |
| 91307 | 0% | 256 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGRIFFIN, AMBER (CEO/CO-OWNER)